Skip to content

Clinical Study on Li Shimao's Sweating Therapy for Cervical Spondylosis of Cold Coagulation Syndrome Type

Clinical Study on Li Shimao's Sweating Therapy for Cervical Spondylosis of Cold Coagulation Syndrome Type

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002022
Enrollment
Unknown
Registered
2025-10-28
Start date
2022-04-02
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diaphoresis

Interventions

Test group:Cold convulsion decoction
Treatment group:cervical traction

Sponsors

Cang Zhou Hospital of Integrated TCM-WM He Bei
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Individuals aged = 20 and = 70 years old, regardless of gender. 2. Meet the diagnostic criteria for cervical spondylosis of traditional Chinese medicine with cold coagulation syndrome. (1) The characteristic of spasmodic pulse is the sinking and tightening of the string. This pulse feels spasmodic when touched. Spalling pulse is the focus of diagnosis for cold coagulation syndrome. (2) The main symptoms diagnosed with cold coagulation syndrome are aversion to cold, neck and shoulder pain and numbness, mainly pain. (3) Fear of cold and other concurrent symptoms are secondary symptoms in the diagnosis of cold coagulation syndrome 3. Meet the diagnostic standards of Western medicine. Symptoms (numbness, pain) and physical signs with root distribution; Positive results in intervertebral foramen compression test or (and) brachial plexus traction test; The imaging findings are basically consistent with clinical manifestations; Excluding pain caused by external cervical lesions (thoracic outlet syndrome, tennis elbow, carpal tunnel syndrome, cubital tunnel syndrome, scapulohumeral periarthritis, long head tenosynovitis of biceps brachii, etc.) 4. The X-ray examination grading is between the early and middle stages. In the early stage, there may be normal or only physiological curvature changes or mild intervertebral space stenosis, with little osteophyte formation; in the middle stage, there may be pointed or lateral hyperplasia of the hooked vertebral joint, intervertebral space stenosis, poor cervical alignment, curvature, intervertebral space stenosis, osteophyte formation at the anterior and posterior edges of the vertebral body, osteosclerosis at the upper and lower edges of the vertebral body (motor endplate), developmental cervical spinal canal stenosis, etc; In the later stage, there may be segmental instability; Left and right oblique films show narrowing and deformation of the intervertebral foramen. Sometimes high-density strip shadows can also be seen at the posterior edge of the vertebral body - ossification of the posterior longitudinal ligament of the cervical spine 5. The patient signs the informed consent form for clinical research.

Exclusion criteria

Exclusion criteria: 1. Merge patients with other types of cervical spondylosis. 2. Patients with combined rheumatic or tumor diseases. 3. Patients with concomitant mental illness. 4. Patients after cervical spine surgery. 5. Those who do not cooperate with treatment during the treatment period. 6. Patients who have been hospitalized for cervical spondylosis more than three times in four years. 7. Apply drugs that affect this trial one week before enrollment. Such as non steroidal analgesic and anti-inflammatory drugs (sustained-release diclofenac sodium tablets, losoprofen sodium tablets, etc.), anti ulcer drugs (omeprazole capsules, etc.), and traditional Chinese medicine for dispelling wind and dispersing cold (Jingshu granules, Gentongping granules, etc.). 8. Those who have not completed treatment and automatically request to withdraw. 9. Pregnant and lactating women. 10. Have severe primary heart, liver, lung, kidney, blood or serious diseases that affect their survival, such as uremia, liver cancer, liver and kidney dysfunction, etc. 11. Suspected or confirmed history of alcohol or drug abuse. 12. According to the judgment of the researcher, other lesions that may reduce the likelihood of enrollment or complicate enrollment, such as frequent changes in the work environment, may lead to loss of follow-up. 13. Allergic constitution, such as a history of allergies to two or more drugs or foods; Or known to be allergic to the ingredients of this medicine. 14. Patients participating in clinical trials of other drugs.

Design outcomes

Primary

MeasureTime frame
Symptom score;

Secondary

MeasureTime frame
Work and life ability;specialist physical signs; hand function scores;

Countries

China

Contacts

Public ContactHu Zhiyong

Cang Zhou Hospital of Integrated TCM-WM He Bei

985746017@qq.com18932792825

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026